Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish
Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab....
BioNTech Stock In Focus After $791.5M Settlement With NIH: Retail Cautious
Retail sentiment on the stock leaned cautious as many commenters noted concerns regarding the mRNA prospects and BioNTech’s capabilities.
BeiGene Stock Eyes 2-Week High After EU Approves Cancer Treatment: Retail Enthusiasm Grows
The latest approval adds to BeiGene’s momentum, marking six EU indications granted in just over a year.